132 related articles for article (PubMed ID: 11344833)
1. Homocysteine elevation with fibrates: is it a class effect?
Harats D; Yodfat O; Doolman R; Gavendo S; Marko D; Shaish A; Sela BA
Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
[TBL] [Abstract][Full Text] [Related]
2. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Dierkes J; Westphal S; Luley C
Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
[TBL] [Abstract][Full Text] [Related]
3. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
[TBL] [Abstract][Full Text] [Related]
4. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C
Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
[TBL] [Abstract][Full Text] [Related]
5. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
8. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
9. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
J Nutr Biochem; 2006 Jun; 17(6):379-84. PubMed ID: 16214329
[TBL] [Abstract][Full Text] [Related]
10. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Hernández C; Lecube A; Barberá G; Chacón P; Lima J; Simó R
Med Sci Monit; 2003 Mar; 9(3):CR114-9. PubMed ID: 12640339
[TBL] [Abstract][Full Text] [Related]
11. Ciprofibrate--a profile.
Betteridge DJ
Postgrad Med J; 1993; 69 Suppl 1():S42-7; discussion S47-9. PubMed ID: 8497456
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of bezafibrate in hyperlipidemia].
Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
[No Abstract] [Full Text] [Related]
14. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
16. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher P; Scheuermann E; Lang W
Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
[TBL] [Abstract][Full Text] [Related]
17. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Zeman M; Zák A; Vecka M; Romaniv S
Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
[TBL] [Abstract][Full Text] [Related]
18. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
[No Abstract] [Full Text] [Related]
19. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
[TBL] [Abstract][Full Text] [Related]
20. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP
Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
